glp-1-directed nmda receptor antagonism for obesity treatment Nature: Dual-active molecules targeting GLP-1R and receptors exhibit superior anti-obesity effects GIPR antagonist antibodies conjugated to

Zepbound was approved by the FDA in November for chronic weight management in adults with obesity or overweight with at least one weight-related condition, such as high cholesterol, high blood pressure, or type 2 diabetes

doi: 10.1038/ncomms14706 281 ArgilesJMBusquetsSStemmlerBLopez-SorianoFJ

The role of obesity in ROS Generation and male infertility

These factors typically resolve within 24 weeks as your body acclimates to the medication and you establish a sustainable eating pattern

NAD+ can support cellular energy, recovery and fatigue management, mental clarity during appetite changes, and overall metabolic resilience

Better Energy and Mood Many patients report more stable energy due to balanced blood sugar and better gut hormone regulation